Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00753519 · ClinicalTrials.gov registry record · Phase 1

Transcranial Magnetic Stimulation to Treat Parkinson's Disease

A Phase 1 study of Parkinson Disease, sponsored by Mark Hallett.

Completed
Registry status
Phase 1
Development phase
28
Enrollment target
1
Study location

NCT00753519: Completed Phase 1 study of Parkinson Disease, sponsored by Mark Hallett.

NCT00753519 is a Phase 1 study of Parkinson Disease that has completed, run by Mark Hallett. The registered enrollment target is 28 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00753519, a Phase 1 study of Parkinson Disease, has completed, sponsored by Mark Hallett.

COMPLETED
Registry status
Phase 1
Development phase
28 participants
Enrollment target
1
Study location

Study Summary

This study will look at the effects of transcranial magnetic stimulation (TMS) on symptoms of Parkinson's disease. TMS is a method of brain stimulation that may be able to change the activity of the nerve cells of the brain. This study will examine the effects of a specific pattern of stimulation called intermittent theta-burst TMS (iTBS), which uses repeated magnetic pulses delivered in short bursts. People with mild to moderately severe Parkinson's disease who are between 40 and 80 years of age and whose main problems are slow movement and stiffness may be eligible for this study. Participants undergo the following tests and procedures: * Random assignment to real or placebo (sham) iTBS treatment. * iTBS sessions (real or sham) 4 times a week for 2 consecutive weeks. For this test, the subject sits in a comfortable chair. A wire coil is held on the subject's scalp, and a brief electrical current is passed through the coil, creating a magnetic pulse that stimulates the brain. The subject hears a click and may feel a pulling sensation on the skin under the coil. There may be a twitch in the muscles of the face, arm or leg. * Test of gait (walk), hand and arm movements before and after each session. The gait test requires walking 10 meters (about 30 yards) in the same corridor with the same shoes. * Extended testing. The first and last gait tests (done before starting iTBS and after the eighth session) require coming off any Parkinson's medication for at least 12 hours before the test. On these test days, subjects also undergo a clinical examination, short neuropsychological test battery, a computer-based reaction time test and depression and quality-of-life rating scales. These procedures are repeated in a follow-up visit 1 month after the last session.

Primary Outcome

Gait speed was assessed by measuring the time it takes to walk 10 meters. Subject's gait speed was measured while on medication and off medication for each group, i.e., real iTBS and sham iTBS. Two trials were averaged for each condition. Patients were instructed to walk fast without taking the risk of falling, wearing the same shoes and consistently using assistive devices if needed. Gait speed was measured at baseline, 1 day post intervention, and 1 month post intervention.

Conditions Studied

Interventions

  • DEVICE Sham iTBS
  • DEVICE Real iTBS

Study Locations (1)

Maryland

  • National Institutes of Health Clinical Center, 9000 Rockville Pike - Bethesda

Trial Details

FieldValue
Enrollment Target 28 participants
Start Date 2008-09
Est. Completion 2009-09
Phase Phase 1
Mark Hallett

1 total trials

What the finished NCT00753519 record still lists

NCT00753519 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Parkinson Disease appearing as the primary indexed condition, and to 2 interventions - of which Sham iTBS is the first listed.

NCT00753519 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT00753519 about?

NCT00753519 is a clinical study titled "Transcranial Magnetic Stimulation to Treat Parkinson's Disease". This study will look at the effects of transcranial magnetic stimulation (TMS) on symptoms of Parkinson's disease. TMS is a method of brain stimulation that may be able to change the activity of the nerve cells of the brain. This study will examine the effects of a specific pattern of stimulation ca...

What is the current status of trial NCT00753519?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2008-09. Estimated completion is 2009-09.

What conditions does trial NCT00753519 study?

This clinical trial studies the following conditions: Parkinson Disease.

What interventions are being tested in trial NCT00753519?

The interventions under investigation include: Sham iTBS (DEVICE), Real iTBS (DEVICE).

Who is sponsoring clinical trial NCT00753519?

This trial is sponsored by Mark Hallett, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00753519 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Parkinson Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00753519's enrollment target sits among peer trials

28 219th of 297 higher than 78 of 297 other Parkinson Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Parkinson Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03471117 · 28 participants · Phase 4

    Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients

  • NCT03523975 · 28 participants · Phase 1

    Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma

  • NCT03608631 · 28 participants · Phase 1

    iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation

  • NCT03810651 · 28 participants · Early Phase 1

    Pencil Beam Scanning in Patients With Renal Tumors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00753519, the US trial registry maintained by the National Library of Medicine. NCT00753519 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.